BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25399327)

  • 1. Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.
    Chen WC; Warner RR; Ward SC; Harpaz N; Divino CM; Itzkowitz SH; Kim MK
    Dig Dis Sci; 2015 Apr; 60(4):996-1003. PubMed ID: 25399327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors.
    Uygun A; Kadayifci A; Polat Z; Yilmaz K; Gunal A; Demir H; Bagci S
    J Surg Oncol; 2014 Feb; 109(2):71-4. PubMed ID: 24165913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.
    Lee HE; Mounajjed T; Erickson LA; Wu TT
    Endocr Pathol; 2016 Sep; 27(3):259-67. PubMed ID: 27306997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 15-year experience with gastric neuroendocrine tumors: Does type make a difference?
    Postlewait LM; Baptiste GG; Ethun CG; Le N; Cardona K; Russell MC; Willingham FF; Kooby DA; Staley CA; Maithel SK
    J Surg Oncol; 2016 Oct; 114(5):576-580. PubMed ID: 27393718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and prognostic features of rectal neuroendocrine tumors.
    Weinstock B; Ward SC; Harpaz N; Warner RR; Itzkowitz S; Kim MK
    Neuroendocrinology; 2013; 98(3):180-7. PubMed ID: 24080744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of endoscopic and surgical resection for foregut neuroendocrine tumors.
    Jung HJ; Hong SJ; Han JP; Kim HS; Jeong GA; Cho GS; Kim HK; Ko BM; Lee MS
    J Dig Dis; 2015 Oct; 16(10):595-600. PubMed ID: 26315879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up.
    Vanoli A; La Rosa S; Miceli E; Klersy C; Maragliano R; Capuano F; Persichella A; Martino M; Inzani F; Luinetti O; Di Sabatino A; Sessa F; Paulli M; Corazza GR; Rindi G; Bordi C; Capella C; Solcia E
    Neuroendocrinology; 2018; 107(2):114-126. PubMed ID: 29895024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment.
    Zhou YJ; Wang QW; Zhang QW; Chen JN; Wang XY; Gao YJ; Li XB
    Front Endocrinol (Lausanne); 2021; 12():658392. PubMed ID: 34122337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.
    Shen C; Chen H; Chen H; Yin Y; Han L; Chen J; Tang S; Yin X; Zhou Z; Zhang B; Chen Z
    BMC Gastroenterol; 2016 Sep; 16(1):111. PubMed ID: 27613657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of gastric and duodenal neuroendocrine tumors.
    Sato Y; Hashimoto S; Mizuno K; Takeuchi M; Terai S
    World J Gastroenterol; 2016 Aug; 22(30):6817-28. PubMed ID: 27570419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine Tumors of the Stomach.
    Corey B; Chen H
    Surg Clin North Am; 2017 Apr; 97(2):333-343. PubMed ID: 28325190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
    Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
    Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Resection of Type 1 Gastric Neuroendocrine Neoplasms and the Risk of Progression in an Endoscopic Surveillance Programme.
    Chin JL; O'Connell J; Muldoon C; Swan N; Reynolds JV; Ravi N; Geoghegan J; Conlon KC; O'Shea D; O'Toole D
    Dig Surg; 2021; 38(1):38-45. PubMed ID: 33260173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of Endoscopic Submucosal Dissection for Gastric Lesions in Norway.
    Rushfeldt C; Aabakken L
    Scand J Surg; 2016 Jun; 105(2):90-6. PubMed ID: 26250354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining surgical indications for type I gastric carcinoid tumor.
    Gladdy RA; Strong VE; Coit D; Allen PJ; Gerdes H; Shia J; Klimstra DS; Brennan MF; Tang LH
    Ann Surg Oncol; 2009 Nov; 16(11):3154-60. PubMed ID: 19727959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric Neuroendocrine Tumors According to the 2019 World Health Organization Grading System: A Single-Center, Retrospective Study.
    Kim Y; Ahn B; Choi KD; Kim BS; Yook JH; Lee GH; Hong SM; Lee JH
    Gut Liver; 2023 Nov; 17(6):863-873. PubMed ID: 36588525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis.
    Chen WC; Warner RRP; Harpaz N; Zhu H; Roayaie S; Kim MK
    Pancreas; 2019 Jan; 48(1):131-134. PubMed ID: 30531243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gastric neuroendocrine tumors: clinical, endoscopic presentation and alternatives of treatment].
    Lazarte R; Poniachik J; Smok G; Contreras J; Gutiérrez L; Csendes A
    Rev Med Chil; 2002 Sep; 130(9):985-92. PubMed ID: 12434645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter.
    Endocrine; ; . PubMed ID: 35895180
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.